News & Press

VenoStent Technology Receives Breakthrough Device Designation by FDA

AP |May, 17, 2022

VenoStent Embarks on Clinical Trial to Improve Success Rate of Vascular Surgery Outcomes

Yahoo Finance |Oct, 26, 2021

Kidney Disease: A Silent (and Costly) Killer

Creative Ventures |Mar, 3, 2021

VenoStent Inks $2.3M

CrunchBase |Feb, 23, 2021

VenoStent Announces $2.3M in Seed Funding to Transform Vascular Access Surgery for Hemodialysis Patients

PRWeb |Feb, 23, 2021

VenoStent Raises $2.3 Million in Seed Funding

Fortune |Feb, 23, 2021

VenoStent Raises $2.2 Million to Begin Clinical Trials

Nashville Business Journal |Feb, 22, 2021

VenoStent wins Prestigious $500,000 KidneyX, Redefining Dialysis Prize

Jul, 22, 2020

VenoStent Accepted into Y Combinator and Closes Oversubscribed SAFE Round

Jun, 24, 2020

VenoStent Awarded Competitive Grant from National Institutes of Health

Apr, 15, 2020

VenoStent Selected as Top 20 MassChallenge Company

Oct, 3, 2019

VenoStent Closes Seed Round; Awarded NSF Phase II Grant

Sep, 4, 2019

VenoStent Awarded LaunchTN Funds

Nov, 13, 2018

Venostent Awarded $224,000 NSF STTR Phase I Grant

Jun, 19, 2018

VenoStent @ Texas New Ventures Competition

May, 30, 2018

Check Our Health Wildcatters 2017 Pitch Day!

Mar, 15, 2018

VenoStent Accepted Into J&J JLabs @ TMC

Jan, 8, 2018

VenoStent Enters Health Wildcatters Accelerator

Sep, 25, 2017
"
How It Works
Company
News
Contact

SelfWrap is currently in the research and development phase and is not available for sale in any country. Investigational Device. Limited by Federal Law to Investigational Use.

© Copyright 2023 VenoStent, Inc.
Contact Usinfo@venostent.com
2450 Holcombe Blvd, Suite J Houston, TX 77021
Follow Us